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Bronchial thermoplasty
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Asthma is a chronic inflammatory disease that affects 300 million people worldwide. Its prevalence ranges 
from 1% to 18% of the population in different countries.1 
The World Health Organization has estimated that 15 
million disability-adjusted life years are lost annually due 
to asthma. Worldwide deaths from asthma are estimated 
at 250 000 per year. Furthermore, asthma is a major cause 
of absence from work in many countries, including United 
States.2
The prevalence of asthma has increased over the last ten 
years around the world. One of the suggested explanations 
to this increment is the western lifestyle hypothesis in 
countries that are going through a transition from a more 
traditional to a more modern lifestyle, as has been described 
in China.3 The prevalence of asthma in China is 2.1%,4 
which results in an addition of 20 million asthmatics. 
Prevalence varies from region to region in China, for 
example, in Jinan it is reported as 1.1%, which is less than 
most western countries; however, asthma control is below 
the goals established by the Global Initiative for Asthma.5 
The case fatality in China reported by GINA is 36.7/100 
000.
The management of patients with asthma can be 
challenging since patient population is diverse when it 
comes to phenotypes and endotypes.6,7 Furthermore, the 
overlapping of asthma with other obstructive pulmonary 
diseases makes it difficult for targeted therapy. The 
cornerstone in the management includes the use of inhaled 
corticosteroids, to keep asthma under clinical control. 
Although, different populations, like Chinese, might have a 
better response to one steroid compared to another.8 Other 
commonly used medications include anti-leukotrienes, 
anti-immunoglobulin E and methylxanthines. Further 
therapies have been tried to target different steps in the 
inflammatory cascade seen in asthma.9,10 Recently, studies 
in the management of airway smooth muscle (ASM) have 
demonstrated that this can be an excellent target to control 
asthma.  Bronchial thermoplasty is one of the most recent 
therapies that targets airway smooth muscle.
AIRWAY SMOOTH MUSCLE
There has been major progress in the field of ASM biology 
over the last few years. ASM has been identified to play a 
significant role in the pathogenesis of obstructive airways 
diseases.11 Further research is underway evaluating 
immunomodulation and airway remodeling of ASM.12
Alterations in the excitation-contraction coupling within the 
myocytes of ASM has been demonstrated in patients with 
asthma compared to normal subjects.13 This may promote 
airway hyperresponsiveness in asthma and other obstructive 
diseases. Furthermore, in vitro studies have shown that 
ASM secrete chemokines  such as CXCL10 and fractalkine, 
as well as cytokines that are important in the autocrine 
loop, perpetuating airway inflammation and angiogenesis, 
that contribute to an already complex immunomodulatory 
role.14 Multiple studies have identified an increase in the 
ASM mass in patients with asthma. This occurred by 
either hypertrophy and/or hyperplasia of myocytes.15,16 
These changes also contribute to hyperresponsiveness and 
bronchoconstriction of airways.
BRONCHIAL THERMOPLASTY
Bronchial thermoplasty (BT) is a new approach for the 
management of severe asthma that specifically targets 
ASM to reduce its mass in order to control airway 
hyperresponsiveness; effect that is seen even by high 
resolution computed tomography.17 This is accomplished 
by bronchoscopic delivered radiofrequency ablation to 
the airway walls.18 The actin-myosin interaction chain is 
disrupted by the high temperatures generated by the high 
frequency alternating current. Through denaturation of 
the motor proteins, disruption of the ASM spasm cascade 
is accomplished.19,20 In previous studies, BT has already 
shown to have long term effects with the reduction of ASM 
mass in healthy dogs and humans.21,22
Other contributing mechanisms of bronchial thermoplasty 
include modification of the extracellular matrix (leading 
to fixation of the airway structure) and reduction in 
mucous gland hyperplasia.23  BT also leads to ablation of 
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“pacemakers” found in large and medium-size airways. The 
additive effects of decreased hyperreactivity is reflected in 
the reduction of downstream modulatory effect in small 
and medium-size airways, which have been hypothesized 
to contribute in the pathophysiology of asthma.24,25
BRONCHIAL THERMOPLASTY: TECHNIQUE
BT is performed via fiberoptic bronchoscopy, with the 
patient under moderate sedation in an outpatient setting. It 
requires three separate bronchoscopic procedures (at two to 
three weeks intervals), in which all the visualized airways 
distal to the mainstem bronchi (down to three mm) are 
treated, with the exception of the right middle lobe. The 
first two sessions are dedicated to treat each lower lobe 
separately, and the third session targets both upper lobes.
The thermal energy utilized in BT is delivered via the 
Alair system (Boston Scientific, Natick, MA, USA), which 
consists of a radiofrequency (RF) electrical generator 
(controller) and a single-use, long, flexible catheter with 
an expandable electrode array attached at one end and a 
deployment handle at the other  (Figures 1 and 2). The 
electrode array expands to contact the airway walls and 
then activated to deliver RF energy for ten seconds each 
time (Figure 3). If improper contact occurs between the 
array and the airway walls the system signals the operator. 
As AF energy is oscillatory electrical current, the patient 
is connected to the Alair controller through an electrode to 
create a closed circuit.  A flexible bronchoscope with a 2.0 
mm working channel is required for the procedure.  As in 
any airway procedure with the transfer of energy, oxygen 
supplementation to the patient should be reduced to less 
than 40% fraction of inspired oxygen to minimize the risk 
of ignition during activation.  The number of activations 
required per procedure varies due to anatomical differences 
in patients as well as operator experience with 40 to 110 
activations occurring per lobe.
Contraindications to BT include presence of an implantable 
electronic device, hypersensitivity to the drugs used during 
the bronchoscopy, and severe comorbidities that increase 
the risk of adverse events (Table 1).  The previous studies 
performed with BT did not include patients who had three 
or more hospitalizations for asthma, three or more lower 
respiratory tract infections, and four or more episodes of 
oral corticosteroids use for asthma exacerbations in the 
previous year.26-28 Patients undergoing BT should be treated 
with a 5-day course of prednisone (50 mg/d), beginning two 
days before the procedure. This has been found to decrease 
the airway inflammation caused by BT and the subsequent 
minor post procedure morbidities.
BRONCHIAL THERMOPLASTY: SAFETY AND 
EFFICACY
After multiple studies in canines with the use of BT 
demonstrating reduction in the airway responsiveness 
to local methacholine provocation,21,29 and persistent 
histologic reduction in the ASM mass,21 the first feasibility 
study in human airways was performed by Miller et al22 in 
eight non-asthmatic patients who underwent lobectomy for 
lung cancer. This study showed a reduction in 50% of the 
ASM mass of the treated airways, with no adverse effects.
Cox et al30 found a significant reduction in airway 
hyperresponsiveness (for up to two years) in sixteen 
patients with mild to moderate asthma who underwent BT. 
Adverse events included airway inflammation that required 
a temporary increase in asthma medications.
Since these studies, three randomized, controlled trials 
have been performed with the use of BT: the Asthma 
Intervention Research (AIR) study, Research in Severe 
Asthma (RISA) study, and the AIR2 trial.26-28 The AIR 
trial26 randomized 112 patients with moderate to severe 
asthma to BT and control.  At twelve months, there were 
significant improvements in the morning peak expiratory 
flow, scores on the Asthma Quality of Life Questionnaire 
(AQLQ), and Asthma Control Questionnaire (ACQ) in 
the BT group compared to 
control. However, there was 
no significant difference in 
airway responsiveness and 
forced expiratory volume in 1 
second (FEV1) between both 
groups. Adverse effects were 
more common in the BT group 
during the first six weeks after 
the treatment, which included 
dyspnea, wheezing, cough, and 
night awakenings; however, 
Table 1. Indications and contraindications of  bronchial thermoplasty
Indications Contraindications
Adults with severe persistent asthma41 defined by:
Daily symptoms
Nightime symptoms more than 7 days per week
Use of short-acting beta 2-agonists several times per day to relieve symptoms
FEV1 <60% predicted; FEV1/FVC reduced >5%
Presence of implanted electronic device
Hypersensitivity  to the drugs used during bronchoscopy
Severe medical conditions that will increase the risk of adverse events during bronchoscopy
Figure 1. Asthmatx AF Controller (Alair System).
Figure 2. Bronchial thermoplasty catheter with electrodes in open position.
Figure 3. Alair catheter opened in airway with electrodes approximating the airway wall.
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there was no significant difference in the treatment and 
control groups during the period of six weeks and twelve m 
onths post treatment. 
In 2007, the RISA trial27 enrolled 32 patients with refractory 
severe asthma who were on high doses of inhaled steroids 
and oral prednisone. The BT group again demonstrated 
a significant reduction in the use of rescue medication 
as well as improvement in AQLQ and ACQ compared 
to control up to 1 year. It was also possible to reduce the 
dose of oral steroids in the bronchial thermoplasty group, 
although this was not statistically significant. The bronchial 
thermoplasty treated group had post-procedure morbidities, 
which included seven hospitalizations due to worsening 
asthma (four patients) and lobar collapse (two patients) that 
required bronchoscopy for suctioning of secretions. In order 
to minimize the subjective effect over the improvement 
of the AQLQ (primary outcome in the AIR2), the AIR2 
trial was performed.28  This was a randomized, double-
blind, sham-controlled study of 288 subjects with severe 
persistent asthma (defined by the Severe Asthma Working 
Group31) on high-dose of inhaled corticosteroids.  However, 
patients with FEV1 post-bronchodilator of less than 65% 
were excluded, as well as patients with four or more asthma 
exacerbations requiring systemic steroids, or three or more 
upper respiratory infections in the previous year. Excluding 
these criteria changes the definition of severe asthma.
The AIR2 trial did show a significant difference in 
improvement of AQLQ in the BT group compared to the 
sham group. There was also a significant improvement 
of AQLQ in the sham group, which was unexpected and 
persisted during the initial twelve months of follow-up. 
The treated group had a significant reduction in severe 
exacerbations (32% reduction vs. sham), unscheduled office 
visits (23% reduction vs. sham), emergency department 
visits (84% reduction vs. sham), hospitalizations (73% 
reduction vs. sham), as well as a statistical reduction in 
days missed from work or school in the BT group for 
the fifty-two weeks follow-up post-treatment. Short-term 
adverse effects related to BT in this study included airway 
inflammation and upper respiratory infections, which were 
similar to previous BT studies.
There are several studies providing data regarding long-
term effects of BT. Thomson et al32 found an absence of 
clinical complications (respiratory events, hospitalizations 
and emergency department visits) over a period of five 
years post BT in forty-five patients treated in the AIR trial. 
Despite the improved clinical condition of patients, there 
was no change in the lung capacity over the same period 
of time. Castro et al33 followed the BT-group patients from 
the AIR2 trial for two years and found the same rate of 
respiratory events compared to the first year post treatment, 
however no comparison with patients with the sham-
group occurred. The AIR2 study’s five years follow-up is 
currently closing worldwide, with long-term data hopefully 
available in 2014.
The United States Federal Drug Administration (FDA) 
approved the use of BT in 2010 for the treatment of severe 
persistent asthma in patients 18 years and older (Table 1), 
with different centers already reporting their favorable 
experiences,34,35 as well as developing histological grading 
systems36 that can be used in the future. However, the 
routine use of this therapy has not been spreading as 
quickly as it is still recognized by most medical insurance 
companies in the United States as experimental and is 
therefore not paid for.  Besides, further questions will need 
to be answered before this technique continues to spread 
worldwide,37 like the long-term effects and the specific 
population that BT can have a significant impact on,38,39 
knowing that failure can also happen.40 
CONCLUSIONS
Given the high prevalence of asthma worldwide, as well 
as its social and economical impact, further investigations 
regarding new therapies for asthma are needed. BT is a 
novel therapy that targets ASM in an attempt to reduce its 
mass and decrease hyperresponsiveness of the airways. 
BT consists of applying radiofrequency ablation, through 
flexible bronchoscopy, to the ASM. Multiple blinded 
controlled randomized studies have demonstrated the 
effectiveness and safety of bronchial thermoplasty. BT is 
a complex bronchoscopic procedure. To maximize safety 
and effectiveness, the procedure should be performed at 
centers with experience in complex airways procedures. 
Further studies assessing long-term effects of BT and in 
which subgroups therapy will have the most impact are still 
pending or needed. 
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